These conditions can lead to increased risk of heart disease, stroke, kidney disease and blindness, among other chronic conditions, particularly if left untreated or poorly treated.
These work in dialysis and help cancer patients, but today Amgen is facing an Food and Drug Administration advisory panel because a large clinical trial showed that instead of improving the prognosis of pre-dialysis kidney patients, Aranesp increased stroke.